- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00456989
Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
Phase I/II Study of Docetaxel (Taxotere) in Combination With Doxorubicin HCI Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer (AIPC)
연구 개요
상세 설명
Each cycle of treatment will consist of four weeks. The 2 types of medicines are given intravenously (in a vein). Doxil is given on the first day of each cycle. Taxotere is given once a week for the first 3 weeks of each cycle. This is followed by a week of rest until the next cycle starts. Treatment is given on an outpatient basis and hospitalization is not anticipated.
Prior to entry on this study, "screening" tests are performed to determine eligibility to participate. This will involve a complete history and physical examination, vital signs, pain assessment, blood tests including CBC (complete blood count), serum chemistry, and PSA (prostate specific antigen), x-rays (chest x-ray, possible plain films of bones if there are abnormal findings on bone scan for clarification), computerized tomography (CT) scans of the abdomen and pelvis, bone scans, a MUGA scan or 2-D echocardiogram, and a quality of life questionnaire.
After treatment starts the following tests are done to regularly monitor for beneficial and toxic effect of the treatment:
Every week: blood tests.
Every month: physical examination, weight, vital signs (blood pressure, respiration, temperature and heart rate) and PSA test.
Every 2 months: pain assessment, quality of life questionnaire, x-rays (chest x-ray and possible pain films of bones if positive findings are seen on bone scan), computerized tomography (CT) scans (abdomen and pelvis) and bone scans.
Participants may continue with any procedures that are part of their regular cancer care. It is anticipated that participants will be in the study for a minimum of 2 months and as long as they are benefiting from the treatment.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- James Graham Brown Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate.
- Androgen-independent disease progression, as shown by:
- A castrate testosterone level of < 40 ng/dl (this measurement is required only for patients treated with medical testicular suppression). If testicular suppression is achieved medically, treatment to maintain castrate levels of testosterone must be applied continuously.
- A PSA level of at least 4 ng/ml, and rising (with an absolute change of at least 1 ng/ml) on two consecutive measurements at least 2 weeks apart prior to study entry.
- Patients must be off anti-androgens such as flutamide (Eulexin) or nilutamide (Nilandron) for at least four weeks, and six weeks for bicalutamide (Casodex), without evidence of response; or have evidence of progression since anti-androgen withdrawal.
- None or one previous cytotoxic therapy is allowed. (For this study, a combination of agents given at the same period of time is considered one chemotherapy treatment)
- Age > 18 years of age.
- Life expectancy of greater than 12 weeks.
- ECOG performance status 0, 1 or 2 (Karnofsky >50%; see Appendix B).
Patients must have adequate bone marrow function as defined below:
- absolute neutrophil count > 1,500/ul
- platelets > 100,000/ul
- hemoglobin > 8 g/dl
Patients must have adequate liver function as defined below:
- total bilirubin normal, albumin > 3.0 g/dl, and no ascites
- AST(SGOT) and ALT(SGPT) and Alkaline Phosphatase must be within the range allowing for eligibility
- Patients must have adequate renal function as defined by a creatinine < 2.5 mg/dl or a creatinine clearance > 30 mL/min (measured or estimated by the Cockroft formula) for patients with creatinine levels above 2.5 mg/dl
- Patients must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Alopecia may not be resolved and peripheral neuropathy (grade 1) may be present.
- Patients must have a MUGA scan or 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. The method used at baseline must be used for later monitoring.
- Patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients who have had two or more prior chemotherapy treatment(s) (For this study, a combination of agents given at the same period of time is considered one chemotherapy treatment).
- Patients receiving any other investigational agent(s).
- Patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis (because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events).
- Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ.
- History of cardiac disease, with New York Heart Association Class II or greater, or clinical evidence of congestive heart failure.
- History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL, the components of Doxil, docetaxel or other drugs formulated with polysorbate 80.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Taxotere and Doxil
Treatment will be repeated every 28 days.
Taxotere is administered on days 1, 8 and 15 (rate: 1 hour).
Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
Treatment will be administered on an outpatient basis.
Treatment will be repeated every 28 days.
Doxil is administered on day 1 (rate: 1mg/min).
Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
|
Treatment will be administered on an outpatient basis.
Treatment will be repeated every 28 days.
Taxotere is administered on days 1, 8 and 15 (rate: 1 hour).
Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
Treatment will be administered on an outpatient basis.
Treatment will be repeated every 28 days.
Doxil is administered on day 1 (rate: 1mg/min).
Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Maximum Tolerated Dose and Toxicity Profile
기간: 2 years
|
2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Response Rate
기간: 7 years
|
Data not analyzed, PI left institution
|
7 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Damian Laber, MD, James Graham Brown Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전립선암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Weill Medical College of Cornell UniversityMillennium Pharmaceuticals, Inc.완전한신경내분비성 전립선암 | 소세포 전립선암 | Prostate Adenocarcinoma Plus > 신경내분비 표지자에 대한 50% 면역조직화학적 염색미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
Taxotere에 대한 임상 시험
-
Hoffmann-La Roche완전한유방암중국, 미국, 남아프리카, 러시아 연방, 태국, 보스니아 헤르체고비나, 체코 공화국, 인도, 폴란드
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZeneca완전한
-
Swiss Group for Clinical Cancer Research완전한식도암 | 위식도 접합부의 선암종스위스, 프랑스, 오스트리아, 독일, 헝가리
-
Catharina Ziekenhuis EindhovenSanofi; Cephalon완전한
-
Sanofi완전한전립선 신생물미국, 프랑스, 브라질, 러시아 연방, 호주, 칠면조, 인도, 오스트리아, 이스라엘, 이탈리아, 멕시코, 영국, 독일, 폴란드, 네덜란드, 남아프리카, 캐나다
-
National University Hospital, Singapore완전한
-
National Cheng-Kung University HospitalChina Medical University Hospital; Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans... 그리고 다른 협력자들모병위암 | 위 선암종 | 화학 요법으로 인한 독성 | 화학 요법의 효과대만